Talk about making the pulse race: Privately held Vitae Pharmaceuticals Inc., with its renin inhibitor program still in the preclinical stage, nailed down a potential $175 million deal with GlaxoSmithKline plc to develop drugs for hypertension and related cardiovascular disorders. (BioWorld Today) Read More
